Tag:
multiple sclerosis
Latest Headlines
Latest Headlines
Investors pocket $761M in deal betting on Biogen's BG-12
Like a lot of biotech investors, Royalty Pharma sees blockbuster potential in Biogen Idec's ($BIIB) experimental BG-12.
Sanofi's Lemtrada beats Rebif in head-to-head MS showdown
Sanofi has rolled out a fresh set of late-stage Lemtrada (alemtuzumab) data demonstrating its superiority to Rebif in a head-to-head matchup for multiple sclerosis.
Biogen Idec builds blockbuster case for new MS drug BG-12
Biogen Idec is backing up its blockbuster expectations for the MS drug BG-12 with a slate of efficacy and safety data gathered in a late-stage study.
Updated: Virtual MS research community emerges
Stakeholders in the development of multiple sclerosis drugs have taken their fight against the neurodegenerative disease online with the launch of a virtual community.
Ono's oral MS drug eliminates brain lesions in promising PhII study
An oral MS drug was credited with eliminating a large percentage of the brain lesions characteristic of the disease.
Watchdog says FDA should consider restricting Gilenya
The Institute for Safe Medicine Practices has zeroed in on Novartis' new multiple sclerosis pill.
Allergan asks FDA for lucrative new Botox indication
Allergan has asked U.S. and European regulators to approve Botox to treat patients with garden-variety overactive bladder, citing two Phase III trials.
Novartis persuades NICE to endorse Gilenya
The U.K.'s cost-effectiveness watchdog has changed its mind about Gilenya. The National Institute for Health and Clinical Excellence at first rejected the Novartis multiple sclerosis pill, in spite of an up-front discount offer. Now, thanks to some new data from the Swiss drugmaker, NICE has decided to recommend the drug instead.
Gilenya market share drops after FDA review
An FDA safety review is taking its toll on Gilenya sales. The Novartis ( $NVS ) multiple sclerosis pill, the first oral therapy for the debilitating disease, lost market share in January after reports that some patients died while using the drug.
Biogen Idec secures FDA nod for Avonex delivery accessory
Biogen Idec ($BIIB) gained the FDA's go-ahead this week for a drug delivery advance and dosing change intended to improve how MS patients take Avonex. They are subtle yet significant ways...
